Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00046176 | A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients | PHASE3 | COMPLETED | 240 | — | — | Aug 26, 2002 | May 17, 2004 | Mar 24, 2020 | 56 | United States, Costa Rica +2 |
| NCT00044577 | New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects | PHASE3 | COMPLETED | 166 | — | — | Jul 16, 2002 | May 25, 2004 | Mar 24, 2020 | 76 | United States, Belgium +7 |
| Name | Type | Description |
|---|---|---|
| abacavir/lamivudine | DRUG | - |
| abacavir | DRUG | - |
| lamivudine | DRUG | - |
| tenofovir | DRUG | - |
Inclusion Criteria: * Currently receiving an initial antiretroviral therapy (ART) regimen composed of the drug abacavir (ABC) 300mg twice a day, plus the drug 3TC (lamivudine) 150mg twice a day in combination with either a protease inhibitor or non-nucleoside reductase inhibitor (NNRTI) for at leas...